ERBB2 and urinary bladder cancer: In a recent basket clinical trial, not all tumours were affected by the same HER mutations, and response to the HER2 inhibitor (neratinib) varied in different tissues: for example, colorectal or bladder cancer with HER2 mutations did not respond.66 In summary, specific drug treatment depends on the tissue context.34